Stratos Wealth Partners LTD. Sells 3,179 Shares of Novo Nordisk A/S (NYSE:NVO)

Stratos Wealth Partners LTD. decreased its position in Novo Nordisk A/S (NYSE:NVO) by 11.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,361 shares of the company’s stock after selling 3,179 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Novo Nordisk A/S were worth $2,182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of NVO. Daymark Wealth Partners LLC grew its holdings in shares of Novo Nordisk A/S by 1.8% during the 3rd quarter. Daymark Wealth Partners LLC now owns 6,402 shares of the company’s stock valued at $762,000 after purchasing an additional 112 shares during the last quarter. Marcum Wealth LLC boosted its position in Novo Nordisk A/S by 2.7% during the third quarter. Marcum Wealth LLC now owns 3,897 shares of the company’s stock valued at $464,000 after buying an additional 104 shares during the period. Wedmont Private Capital grew its stake in shares of Novo Nordisk A/S by 7.8% during the third quarter. Wedmont Private Capital now owns 11,120 shares of the company’s stock valued at $1,310,000 after buying an additional 809 shares during the last quarter. Sanibel Captiva Trust Company Inc. increased its holdings in shares of Novo Nordisk A/S by 6.5% in the third quarter. Sanibel Captiva Trust Company Inc. now owns 8,993 shares of the company’s stock worth $1,071,000 after buying an additional 547 shares during the period. Finally, Boston Common Asset Management LLC lifted its stake in shares of Novo Nordisk A/S by 8.9% in the 3rd quarter. Boston Common Asset Management LLC now owns 50,293 shares of the company’s stock valued at $5,988,000 after acquiring an additional 4,119 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on NVO. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Down 0.9 %

Shares of NVO opened at $86.39 on Friday. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm’s 50-day moving average price is $91.86 and its 200-day moving average price is $111.83. The firm has a market capitalization of $387.66 billion, a price-to-earnings ratio of 27.96, a PEG ratio of 0.93 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.16 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.